相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction
Solene E. Boitard et al.
CANADIAN JOURNAL OF CARDIOLOGY (2022)
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction
M. A. ap Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Targeting Brain Aminopeptidase A: A New Strategy for the Treatment of Hypertension and Heart Failure
Yannick Marc et al.
CANADIAN JOURNAL OF CARDIOLOGY (2020)
Apilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension
Michel Azizi et al.
JOURNAL OF HYPERTENSION (2019)
Brain renin-angiotensin system blockade with orally active aminopeptidase A inhibitor prevents cardiac dysfunction after myocardial infarction in mice
Solene Emmanuelle Boitard et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2019)
Efficacy and Safety of Firibastat, A First-in-Class Brain Aminopeptidase A Inhibitor, in Hypertensive Overweight Patients of Multiple Ethnic Origins A Phase 2, Open-Label, Multicenter, Dose-Titrating Study
Keith C. Ferdinand et al.
CIRCULATION (2019)
Specific Inhibition of Brain Angiotensin III Formation as a New Strategy for Prevention of Heart Failure After Myocardial Infarction
Frans H. H. Leenen et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2019)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug
Fabrice Balavoine et al.
CLINICAL PHARMACOKINETICS (2014)
Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction
Bing S. Huang et al.
CARDIOVASCULAR RESEARCH (2013)
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Patrick T. O'Gara et al.
CIRCULATION (2013)
The Epidemiology of Congestive Heart Failure: Contributions from the Framingham Heart Study
Syed S. Mahmood et al.
GLOBAL HEART (2013)
Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction -: The Survival and Ventricular Enlargement (SAVE) study
MP Tokmakova et al.
CIRCULATION (2004)
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
MA Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAL randomised trial
K Dickstein et al.
LANCET (2002)
分享论文
